Heron Therapeutics | HRTX - Capital Ordinário





Capital Ordinário Alterar Data
ALKERMES USD 165.61M 503K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amarin USD 20.81M 13K 2025-12
ANI Pharmaceuticals USD 22.49M 760K 2025-12
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 135.7M 2.44M 2025-09
Eisai JPY 282.11M 1000 2025-12
Emergent BioSolutions USD 100K 0 2023-06
Esperion Therapeutics USD 245.22M 39.79M 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.49B 15.79M 2025-09
Nektar Therapeutics USD 19K 0 2024-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Omeros USD 611K 17K 2023-12
Pacira USD 41.12M 1.85M 2025-12
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Roche Holding CHF 795.62M 699.54K 2025-12
Surmodics USD 716K 4K 2024-09
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Veracyte USD 79.05M 377K 2025-12
Vertex Pharmaceuticals USD 254M 0 2025-12